Andrey Doronichev

CEO at Optic          


CEO of Optic, a leading provider of AI-powered drug discovery infrastructure. He is leading the charge in helping pharmaceutical companies accelerate their R&D with AI-driven small-molecule drug discovery.

Prior to founding Optic, Andrey held key leadership roles at Google, where he was the founding product leader at YouTube's Mobile Applications team and Google's VR/AR/Stadia teams.

Under Andrey's leadership, Optic has assembled a world-class team of AI experts and life science professionals. Together, they are building a powerful platform that empowers researchers to accelerate drug discovery and identify promising new therapeutics.

Optic is backed by VCs of Amazon, Google, Twitter and crypto native Pantera Capital.

Contributing Author   in
AI & Digital  

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Articles from Andrey

AI Is Key to Democratizing Drug Discovery

   4357
AI Is Key to Democratizing Drug Discovery

The global drug development landscape is bustling, with over 20,000 biotechs competing for investor attention. Now more than ever, having a decisive edge is crucial to bring the right molecule from target to lead candidate to approved drug. Fast.

Generative AI could be the answer. The best way to fight Eroom’s law is to shift as much work as possible into in-silico territory and let Moore’s law work its magic. Understanding how to leverage this technology will distinguish the winners from those left behind.